Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Systematic Review

Multicenter Study

Meta-Analysis

Review

Network Meta-Analysis

Clinical Trial, Phase III

Comparative Study

Clinical Trial, Phase II

Clinical Trial

Publication Year

From

Quick links

Individual year

2025

2024

2022

2021

2020

2019

2018

2017

2015

2014

2013

2012

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Lurasidone Hydrochloride""[mesh_terms]

23 Results

Searching titles within these results

Efficacy and safety of lurasidone in schizophrenia: pooled analysis of European results from double-blind, placebo-controlled 6-week studies.

Fabrizio Calisti, Agnese Cattaneo, Mariangela Calabrese, Yongcai Mao, Michael Tocco, Andrei Pikalov, Robert Goldman

International clinical psychopharmacology 2022;37(5):215-222

Full Text

Abstract

Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force.

Eduard Vieta, Allan H Young, Vicent Balanzá-Martínez, Kamilla W Miskowiak, Ida Seeberg, Mette B Jensen, Caterina Del Mar Bonnin, Christopher R Bowie, Andre F Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher, Gregor Hasler, Beny Lafer, Kathryn E Lewandowski, Carlos López-Jaramillo, Anabel Martinez-Aran, Roger S McIntyre, Richard J Porter, Scot E Purdon, Ayal Schaffer, Paul Stokes, Tomiki Sumiyoshi, Ivan J Torres, Tamsyn E Van Rheenen, Lakshmi N Yatham, Lars V Kessing, Katherine E Burdick

Bipolar disorders 2022;24(4):354-374

Free Full Text

Abstract

Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis.

Daisy Ng-Mak, Vanita Tongbram, Kerigo Ndirangu, Krithika Rajagopalan, Antony Loebel

Journal of comparative effectiveness research 2019;7(8):737-748

Free Full Text

Abstract

Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression.

Melissa P DelBello, Aditi Kadakia, Vincent Heller, Rajpal Singh, Katsuhiko Hagi, Tadashi Nosaka, Antony Loebel

Journal of the American Academy of Child and Adolescent Psychiatry 2022;61(2):243-254

Full Text

Abstract

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies.

Isabella Costamagna, Fabrizio Calisti, Agnese Cattaneo, Jay Hsu, Michael Tocco, Andrei Pikalov, Robert Goldman

European psychiatry : the journal of the Association of European Psychiatrists 2021;64(1):e35

Free Full Text

Abstract

Lurasidone versus typical antipsychotics for schizophrenia.

Magdalena Koperny, Dawid Storman, Krzysztof Styczeñ, Wojciech Datka, Rafal R Jaeschke

The Cochrane database of systematic reviews 2025;1(1):CD012429

Full Text

Abstract

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.

Greg W Mattingly, Peter M Haddad, Michael Tocco, Jane Xu, Debra Phillips, Andrei Pikalov, Antony Loebel

BMC psychiatry 2020;20(1):199

Free Full Text

Abstract

LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY.

Terence A Ketter, Kaushik Sarma, Robert Silva, Hans Kroger, Josephine Cucchiaro, Antony Loebel

Depression and anxiety 2018;33(5):424-34

Free Full Text

Abstract

Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan.

Nakao Iwata, Reiji Yoshimura, Taro Kishi, Kenji Sakuma, Makoto Okuya

Neuropsychopharmacology reports 2021;40(4):417-422

Free Full Text

Abstract

Umbrella Review: Association Between Antipsychotic Drugs and Metabolic Syndrome Hallmarks in Children and Adolescents.

Carla Carnovale, Vera Battini, Claudia Santoro, Maria Pia Riccio, Sara Carucci, Maria Nobile, Pietro Formisano, Carmela Bravaccio, Alessandro Zuddas, Emilio Clementi, Marco Pozzi, Simone Pisano

Journal of the American Academy of Child and Adolescent Psychiatry 2024;63(3):313-335

Free Full Text

Abstract

Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety.

David J Greenblatt, Jerold S Harmatz, Michael J Ryan, Christina R Chow

Journal of clinical psychopharmacology 2018;38(4):289-295

Full Text

Abstract

Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression.

Meihua Lin, Keke Huang, Xuanwei Li, Jian Xie, Shaohua Hu, Xiao Li, Qingwei Zhao, Chunxiao Dai, Yaoyang Fu, Yinbo Li, Chengcheng Zhou

Journal of Zhejiang University. Science. B 2025;26(1):26-38

Free Full Text

Abstract

Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study.

Brent P Forester, Martha Sajatovic, Joyce Tsai, Andrei Pikalov, Josephine Cucchiaro, Antony Loebel

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2019;26(2):150-159

Free Full Text

Abstract

Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Leslie Citrome, Terence A Ketter, Josephine Cucchiaro, Antony Loebel

Journal of affective disorders 2014;155():20-7

Full Text

Abstract

Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials.

Jiang Li, Antony Loebel, Herbert Y Meltzer

Schizophrenia research 2019;199():203-213

Full Text

Abstract

Results: 1 – 15 / 23

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Lurasidone Hydrochloride""[mesh_terms]

Efficacy and safety of lurasidone in schizophrenia: pooled analysis of European results from double-blind, placebo-controlled 6-week studies.

Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force.

Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis.

Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression.

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies.

Lurasidone versus typical antipsychotics for schizophrenia.

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.

LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY.

Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan.

Umbrella Review: Association Between Antipsychotic Drugs and Metabolic Syndrome Hallmarks in Children and Adolescents.

Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety.

Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression.

Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study.

Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials.

Results for
""Lurasidone Hydrochloride""[mesh_terms]